Breast Diseases
Also known as: Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Breast Diseases Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are breast diseases? Breast diseases include various conditions and changes in your breast.
- 2 Real-world patient consensus: Synonyms for Breast Diseases (N60.09): Disorder, Syndrome, Diseases (Cancer & Oncology).
- 3 Typical cash cost range: Clinicians assessing Breast Diseases focus on somatic oncogenic driver in Breast Diseases (N60.09: mutations) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Breast Diseases: Complete Blood Count in Breast Diseases (N60.09: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (N60.09)) and Comprehensive Metabolic & in Breast Diseases (N60.09: Organ Function Panel).
Ask our AI Specialists anything about Breast Diseases
What Is Breast Diseases?
What are breast diseases? Breast diseases include various conditions and changes in your breast. Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges of fluids that are not breast milk. Although many women fear cancer , most breast changes are benign, meaning they are not cancer. These breast changes are known as benign breast disease. See your health care provider if you have a breast lump, pain, discharge, or skin irritation. Minor and serious breast problems often have similar symptoms and may need treatment.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Breast Diseases (ICD-10 N60.09) is driven by somatic oncogenic driver in Breast Diseases (N60.09: mutations); Cross-referenced with NIH MeSH (Breast Diseases, Mastitis), specialists in Cancer, Oncology & Supportive Care monitor Comprehensive Metabolic & in Breast Diseases (N60.09: Organ Function Panel) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Cysts are fluid-filled lumps that may be tender
- • Fibroadenomas are solid, round, rubbery lumps that easily move when pushed, occurring most in younger women
- • Presentation of Breast Diseases (N60.09): abnormality detected early in Breast Diseases (N60.09: on age-appropriate screening)
- • Secondary Breast Diseases clinical sign: persistent painless lump, in Breast Diseases (N60.09: non-healing ulcer/mole change,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Breast Diseases Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N60.09 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Breast Diseases (N60.09: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (N60.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Breast Diseases (N60.09: Organ Function Panel) | Preserved renal/hepatic clearance (N60.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Breast Diseases (N60.09: Genomic Staging) | Guideline-concordant surveillance (N60.09) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Breast Diseases
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Docetaxel Docivyx, Beizray • RxCUI 1001405 | Microtubule Inhibitor | 91% | $1.1500 | $ 55.08 /mo |
| Tamoxifen Citrate Soltamox, Nolvadex • RxCUI 198240 | Estrogen Agonist/Antagonist | 91% | $0.1255 | $ 8.21 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Breast Diseases)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of concomitant statin treatment in postmenopausal patients with hormone: What a 3,420-Participant Study Found According to this analysis, hydrophilic statins showed a detrimental effect on DFS in the main model, which was attenuated after correction for confounders. ESMO open • 2022-04-15 • Phase III Randomized Trial | N = 3,420 | 96/100 | PMID 35334418 ↗ |
| New Insights on TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative,: What a 412-Participant Study Found TQB2440 showed equivalent efficacy, comparable safety, PK, and immunogenicity profiles to reference pertuzumab in the neoadjuvant treatment of patients with HER2-positive early or locally advanced breast cancer. ESMO open • 2026-01-15 • Phase III Randomized Trial | N = 412 | 93/100 | PMID 41401771 ↗ |
| New Insights on Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or: What a 275-Participant Study Found These findings support lerociclib plus fulvestrant as a treatment option for patients with HR+/HER2- endocrine-resistant advanced breast cancer (ABC). Nature communications • 2025-01-16 • Phase III Randomized Trial | N = 275 | 93/100 | PMID 39820749 ↗ |
| New Insights on Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer: What a 509-Participant Study Found Final OS data indicate that the PFS improvement shown in the primary analysis did not translate into an OS benefit. European journal of cancer (Oxford, England : 1990) • 2024-03-15 • Phase III Randomized Trial | N = 509 | 93/100 | PMID 38309017 ↗ |
| Can This Approach Help? Inside the Latest Research on 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast Nature Medicine, Published online: 29 October 2026; doi:10.1038/s41591-026-04723-w A 5-year secondary analysis of the phase 2 PHERGain trial supports the clinical utility of a PET-guided adaptive strategy for treatment de-escalation in HER2-positive early brea Nature Medicine • 2026-10-29 • Peer-Reviewed Journal (Longevity & Biotech) | Multi-cohort | 92/100 | PMID NATURE_MED-4248748391 ↗ |
Breast Diseases Patient Community & “People Like Me” Threads
Filter Breast Diseases community threads and patient logs by age, biological sex, dosage, and treatment duration.